

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

April 3, 2024

Evert Schimmelpennink President and Chief Executive Officer LENZ Therapeutics, Inc. 445 Marine View Ave., Ste. #320 Del Mar, California 92014

Re: LENZ Therapeutics, Inc.
Registration Statement on Form S-1
Filed March 29, 2024
File No. 333-278393

Dear Evert Schimmelpennink:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Ben Capps